<?xml version="1.0" encoding="UTF-8"?>
<p id="p0095">Given this complexity, it is clear that a piecemeal pharmaceutical approach is misguided; foundationally improving metabolic health is key to resilience against this pandemic and those we will inevitably face in the future. It is important to remember that influenza and other bacterial and viral illnesses also discriminate against people with diabetes, with these individuals being six times more likely to need hospitalization during influenza epidemics than people without diabetes [
 <xref rid="bb0110" ref-type="bibr">22</xref>]. We must commit to evidence based dietary and lifestyle strategies that prevent and reverse disease, which have been shown to be highly effective (some studies showing reversal of diabetes in as little as 10â€¯weeks of coaching and nutritional interventions) [
 <xref rid="bb0115" ref-type="bibr">23</xref>]. Strategies that involve optimization of nutrition, exercise [
 <xref rid="bb0120" ref-type="bibr">24</xref>], sleep hygiene [
 <xref rid="bb0125" ref-type="bibr">25</xref>], stress management [
 <xref rid="bb0130" ref-type="bibr">26</xref>], and toxin exposure [
 <xref rid="bb0135" ref-type="bibr">27</xref>] all play a role in management of metabolic disease, and yet have been largely missing from existing literature on management of diabetes in the setting of COVID-19.
</p>
